{"disease":{"id":"pituitary-dwarfism","name":"Pituitary dwarfism","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"genotropin","indication_name":"Pituitary dwarfism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnitrope","generic_name":"Somatropin","company_name":"Serono","drug_phase":"marketed","molecular_target":"Dimeric GH receptors on cell membranes of target tissues","drug_class":"Recombinant human growth hormone","quality_score":10,"revenue":"446","mechanism":"Somatropin binds dimeric GH receptors on target cells, inducing intracellular signaling and GH-dependent protein synthesis including IGF-1."},{"drug_id":"omnitrope","indication_name":"Pituitary dwarfism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omnitrope","company_name":"Sandoz","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"sermorelin","indication_name":"Pituitary dwarfism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geref","generic_name":"sermorelin","company_name":"","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"sermorelin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"somatropine","indication_name":"Pituitary dwarfism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"somatropine","company_name":"Sanofi","drug_phase":"phase_3","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01009905","title":"An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)","phase":"","overall_status":"COMPLETED","enrollment_count":22960,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}